Good Life Project – Future of Medicine: Regenerative Medicine, Stem Cells & Peptides

Host: Jonathan Fields
Guest: Dr. Adeel Khan
Air Date: November 17, 2025

Episode Overview

In this episode of Good Life Project’s "Future of Medicine" series, Jonathan Fields speaks with Dr. Adeel Khan, a pioneering physician in regenerative medicine. They explore the rapidly evolving landscape of regenerative therapies, including stem cells, peptides, gene therapy, and how technology such as AI is accelerating breakthroughs. The conversation focuses on demystifying the science, dissecting myths, clarifying ethical debates, and exploring both current applications and future potentials of regenerative medicine to heal, slow aging, and even reset our biology.

Key Discussion Points & Insights

Introduction to Regenerative Medicine

• Definition & Philosophy

  • Dr. Khan frames regenerative medicine as “rebooting the body's original design. We're just giving you the right signals, the right cells, the right tools so your body can heal itself.” [04:54]
  • Emphasis on stimulating the body’s inherent healing mechanisms, not limited to advanced treatments but including ancient practices like fasting and non-invasive modalities (e.g., shockwave therapy).

• Past, Present, and Future

  • Regenerative practices have roots in ancient healing but are gaining new legitimacy due to advancements in cellular biology, particularly in understanding different cell types and pathways.
  • “It's both the future, but it's also the ancient past simultaneously.” – Jonathan Fields [05:50]

The Evolution and Reality of Stem Cells

• Types of Stem Cells & Key Discoveries

  • Mesenchymal Stem Cells (MSCs): Historically believed to be versatile; sourced from bone marrow, fat, and umbilical tissue.
  • Induced Pluripotent Stem Cells (iPSCs): Laboratory-created cells with potential to become any cell type, but high tumor risk.
  • MUSE cells (“The Tesla of Stem Cells”): “Muse cells... can turn into any cell in your body, but they're non-cancerous or non-tumorigenic.” [10:14]
    • Discovered by Prof. Mari Dezawa in 2010, MUSE cells combine pluripotency with safety.

• Effectiveness and Misconceptions

  • Many clinic-offered stem cell treatments (especially those extracting cells from older patients’ own bodies) may not provide potent results due to cellular aging.
  • “After age 50...they can even become pro-cancerous. So you really don't want to be taking your old stem cells and then culture expanding them too...” [16:43]
  • Most “stem cell” injections are actually "medicinal signaling cells,” not true regenerative stem cells.
    • “The name unfortunately needs to be changed...” [14:43]

• Why Isn't the Latest Used Everywhere?

  • Scientific suppression and inertia: “Professor Yamanaka...saw her cell (MUSE) discovery as a competitor and went out of his way to make sure her work wasn't as well known as his.” [17:44]
  • Slow shifts in medical practice and knowledge gaps in the wider practitioner base.

The Promise and Practice of MUSE Cells

• Source and Safety

  • Best harvested from umbilical cord tissue (donated, post-birth), allowing for "off-the-shelf" standardized, potent cellular therapy.
  • Unique HLAG antigen enables them to evade immune rejection—“Babies express this to prevent the mom's cells from attacking the baby.” [24:30]
  • High quality standards: “90% of the samples...are thrown out because they don't have enough new cells or...high enough quality.” [25:44]

• Accessibility & Legal Update

  • Florida legalizing allogeneic (donor-sourced) therapies; MUSE cells expected to become widely available soon. [26:03]

• Applications

  • Chronic pain, osteoarthritis, autoimmune conditions, neurodegenerative diseases (Alzheimer’s, Parkinson’s), and even challenging “invisible” diseases like fibromyalgia and long Covid. “90% success rate, which is really high for chronic issues.” [29:18]
  • Systemic delivery: MUSE cells possess a “homing mechanism” that leads them to sites of tissue damage via chemical signals, potentially opening applications in post-heart attack repair and stroke recovery. [31:10]

Peptides: Old Molecules, New Buzz

• What They Are & Why They Matter

  • Tiny proteins that act as “bioactive signals” for healing, metabolism, and more; insulin and Ozempic are classic examples.
  • Exploding popularity despite minimal traditional clinical trial data: “The real world evidence is so robust and strong because it works for so many people...” [39:42]
  • Peptides for gut healing (BPC157), soft tissue repair (TB500), and mitochondrial health (SS31) frequently cited.
    • “BPC157 is a body protection complex...helps with healing and regeneration.” [42:17]

• Access & Quality Concerns

  • Most are unpatentable, so little pharmaceutical interest or investment in clinical trials. Quality is variable; consumers are warned of counterfeit or underdosed products—“There's literally companies that make peptides and have zero peptides in there.” [47:11]
  • Dr. Khan recommends physician oversight and third-party validation (e.g., FINRIC.com).

• Future: Patches Over Injections

  • Advances in delivery methods, like peptide patches, are making use more accessible.

Exosomes, Gene Therapy, and the Next Frontier

• Exosomes

  • The “broth” produced by stem cells; cell-free but rich in regenerative signals.
    • “If you have a chicken broth, the meat is the stem cells and the broth is the exosomes.” [47:57]
  • Cheaper and DNA-free; less potent but an option for some.

• Gene Therapy

  • Current applications focus on "additive gene therapy"—adding copies of beneficial genes (e.g., Follistatin for muscle loss, Clotho for brain health), mostly outside the U.S.
  • “Gene therapy—think of it as turning your cell into a factory to produce more of that peptide.” [50:11]
  • Ongoing research in gene editing (CRISPR, "prime editing"), but not yet ready for clinical use due to complexity and risks.

• Synergy and a Systems Approach

  • Blending stem cells, exosomes, peptides, and gene therapy tailored to each patient: “That's exactly what we do on a daily basis.” [49:34]
  • Emphasis on holistic treatment—regenerative medicine as a “tool in the toolbox,” not a single-cure-all. [35:14]

Access, Ethics & The Role of Technology

• Affordability & Scaling

  • Currently expensive and mostly available to wealthy/”early adopter” patients, but as manufacturing scales (with robotics/AI) costs are expected to “come down by an order of magnitude...in the next 10 years.” [55:47]
  • Regulatory approvals (and insurance coverage) key to mass adoption.

• Ethical & Safety Considerations

  • Use of donor umbilical tissue is voluntary and non-invasive—“no aborted fetuses,” high screening and safety standards. [25:35]
  • Potential risks from unregulated products and unproven providers.

• Artificial Intelligence

  • AI is already accelerating cellular reprogramming breakthroughs, as in the discovery of new, more efficient reprogramming methods. [57:21]
  • “That's only going to happen more and more in regenerative medicine and all medicine.” [57:59]

• Vision for the Future

  • Dr. Khan imagines a world “where these infusions for longevity are covered by insurance because they reduce the risk of chronic diseases, which ultimately helps the society at large.” [58:07]

Notable Quotes & Memorable Moments

• “We're just giving you the right signals, the right cells, the right tools so your body can heal itself.”
  — Dr. Adeel Khan [04:54]

• “Stem cell exhaustion...is one of the hallmarks of aging. So as you get older...the ability for your stem cells to do their job decreases...So that's one of the reasons we age.”
  — Dr. Khan [12:35]

• “After age 50...they can even become pro-cancerous. So you really don't want to be taking your old stem cells and...infusing them back in, you may actually be doing harm to the patient.”
  — Dr. Khan [16:43]

• “Babies express this [HLAG antigen] to prevent the mom's cells from attacking the baby. So it's a protective mechanism...MUSE cells are considered immuno-privileged.”
  — Dr. Khan [24:30]

• “90% of the samples…are thrown out because they don't have enough new cells or...high enough quality.”
  — Dr. Khan [25:44]

• “Chronic pain is definitely where this has definitely shines the most...90% success rate, which is really high for chronic issues.”
  — Dr. Khan [29:18]

• “The MUSE cells, they're kind of like the emergency paramedics. They can sense a signal that there's tissue damage...and know where to go.”
  — Dr. Khan [31:10]

• “You want to look at the body as a whole system...you need a lot of tools. It's not as simple as just throw stem cells at it because that's not going to work.”
  — Dr. Khan [35:14]

• “The real world evidence is so robust and strong because it works for so many people.”
  — Dr. Khan [39:42]

• “All these people are getting away with it because right now the FDA just hasn't cracked down. But as big pharma gets their hands into the peptide world, you bet they're going to start cracking down on these manufacturers.”
  — Dr. Khan [46:13]

• “If you have a chicken broth, the meat is the stem cells and the broth is the exosomes.”
  — Dr. Khan [47:57]

• “Gene therapy—think of it as turning your cell into a factory to produce more of that peptide.”
  — Dr. Khan [50:11]

• “That's exactly what we do on a daily basis.”
  — Dr. Khan (on combining stem cells, exosomes, and peptides) [49:34]

• “AI came up with a way to [do] cellular reprogram[ming]...50 times...more effective than the Yamanaka reprogramming technology.”
  — Dr. Khan [57:26]

• “I'd love to see in 10 years...these infusions for longevity are covered by insurance because they reduce the risk of chronic diseases.”
  — Dr. Khan [58:07]

Timestamps: Important Segments

[04:54] – Dr. Khan defines regenerative medicine
[08:48] – History and realities of stem cell therapies
[10:14] – Discovery and properties of MUSE cells
[12:35] – Aging, stem cell exhaustion, and implications
[14:43] – Why “stem cell” injections may not work for older adults
[24:30] – Immunological safety of MUSE cells
[26:03] – Legal and clinical status in the US (Florida case)
[29:18] – Conditions effectively treated by MUSE cells
[31:10] – MUSE cells’ “homing” ability and clinical trials for heart/stroke
[33:45] – Neurodegenerative conditions and future clinical trial directions
[35:35] – Partial epigenetic reprogramming: the next breakthrough
[39:42] – The peptide revolution
[42:17] – BPC157, TB500: “Wolverine” peptides and applications
[44:31] – Why peptides lack clinical trials
[46:13] – Peptides, pharma, and future regulation
[47:57] – Exosomes explained
[50:11] – Gene therapy and muscle/brain anti-aging
[55:47] – Access, costs, and future scalability
[57:21] – AI’s role in regenerative breakthroughs
[58:07] – Vision for regenerative medicine: accessibility, insurance, scale

Summary Takeaway

Regenerative medicine stands at a transformative crossroads, merging ancient healing principles with revolutionary advances in biology, cell therapy, and technology. Dr. Adeel Khan and Jonathan Fields unravel its promise—and its pitfalls—offering listeners a grounded look at stem cells (especially MUSE cells), peptides, gene therapies, and the future role of AI. The conversation is both hopeful and cautionary: these therapies are poised to bring radical healing and longevity but require vigilant education, ethical oversight, and systemic innovation before they become accessible to all.

For more:
Tune in next week as the series continues with Dr. Ami Bhatt on AI in cardiovascular medicine.
Follow Good Life Project on your favorite Podcast app to keep up with the Future of Medicine series.